Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer

Datopotamab deruxtecan was associated with lower rates of high-grade TRAEs vs chemotherapy in the phase 3 TROPION-Breast01 trial.

Related Keywords

,James Cayne ,Komal Jhaveri ,Early Drug Development Service ,Endocrine Therapy Research Program ,Breast Cancer Congress ,Cancer Congress ,James Cayne Chair ,Junior Faculty ,Memorial Sloan Kettering Cancer Center ,